[Source: Pharmabiz.com] – Apthera, Inc has entered into a commercial license agreement with Kwang Dong Pharmaceutical Co, Ltd for use of Apthera’s NeuVax, a peptide-based cancer immunotherapy product.
Under the terms of the agreement, Kwangdong will receive a license to sell NeuVax in South Korea for the treatment of early-stage breast cancer. Apthera will receive milestone payments as well as a royalty on commercial sales. Kwang Dong has also made an equity investment in Apthera and will invest in a future round of financing.
For more information click here